Macter International Limited (MACTER): 1HFY25 Corporate Briefing Takeaways - By Taurus Research
Mar 11 2025
Taurus Securities
- MACTER, a prominent pharmaceutical company in Pakistan, initially established its operations by acquiring the OTC portfolio of MACTER International Limited. Over time, the company expanded its capabilities, transitioning towards a stateof-the-art manufacturing facility. Notably, MACTER is the first and only approved manufacturing facility in Pakistan for the lyophilization of biologicals.
- MACTER reported revenue of ~PKR 4.9Bn in 1HFY25, a 37%YoY increase from PKR 3.5Bn. Margins rose by 4ppts to 45%, driven by a better sales mix and strong export performance. The Company achieved a PAT of ~PKR 392Mn, doubling from PKR 195Mn last year, thanks to higher sales, improved gross margins, and effective cost optimization efforts coupled with an effective pricing strategy.
- MACTER's current product portfolio features a range of leading medications, including Titan, MacEpo, Venticort, Relaxin, and Omeprazole. In FY24, after receiving long-awaited regulatory approvals, MACTER successfully launched several new products, such as Seglutide (Semaglutide), and Inhixa. Notably, the launches of these two products have rapidly gained significant market share, providing substantial benefits to the Company, as supported by positive performance results
Current:
Open:
Volume:
Change: ()
High:
Low:
52 Week High:
Vol Avg(12 m):
Free Float:
52 Week Low:
Market Cap:
Total Share:
Relative Strength Index (RSI)
RSI:
MACD Signals
MACD DAILY:
MACD WEEKLY:
Simple Moving Avg (SMA)
SMA(10):
SMA(30):
SMA(60):
SMA(200):
Performance
One Month:
Three Months:
Six Months:
Twelve Months:
Support & Resistance
Support 1:
Resistance 1:
Support 2:
Resistance 2:
High & Lows
Period
High
Low